# What did tesamorelin trials test beyond belly fat?

Published November 14, 2026 · Updated November 14, 2026 · Data as of October 30, 2026

In a trial in people with HIV and non-alcoholic fatty liver disease (NAFLD), [tesamorelin](https://pepbank.io/p/tesamorelin) reduced hepatic fat fraction more than placebo over 12 months. [1] Other trials in people measured trunk muscle, insulin response and neurocognitive performance. [2, 3, 4] In a trial in adults with type 2 diabetes, insulin response did not change versus placebo. [3] In a cognition trial in people with HIV, only a trend appeared, and it was not significant. [4]

## Key points

- In trials in people with HIV and excess abdominal fat, tesamorelin reduced visceral fat more than placebo over 26 weeks. [5, 6]
- In a trial in people with HIV and NAFLD, tesamorelin reduced liver fat more than placebo over 12 months. [1]
- In a trial in people with HIV, tesamorelin responders had greater gains than placebo in the density of four trunk muscle groups. [2]
- In a trial in adults with type 2 diabetes, insulin response did not change versus placebo over 12 weeks. [3]
- In a trial in adults with HIV, the trend toward better neurocognitive performance was not significant versus standard of care. [4]
- As of October 30, 2026, PepBank holds 37 publications with findings in people, 5 in animals and 23 registered trials. [7]

## What did the visceral fat trials find?

The FDA approved Egrifta, a tesamorelin product, in the US in 2010. Its listed use is reducing excess abdominal fat in adults with HIV and lipodystrophy. [8, 9]

A pooled analysis of two trials in patients with HIV and excess abdominal fat compared tesamorelin with placebo. At week 26, visceral adipose tissue (VAT) changed by -24 square centimeters with tesamorelin. It changed by 2 square centimeters with placebo. The treatment effect on VAT was -15.4%. [5]

In another trial in patients with HIV, VAT changed by -15.2% with tesamorelin over 26 weeks and by 5% with placebo. [6] In a third trial in adults with HIV, VAT changed by -10.9% with tesamorelin over 6 months and by -0.6% with placebo. [10]

In the pooled trials in patients, abdominal fat under the skin did not change significantly versus placebo. It changed by -2 square centimeters with tesamorelin and 2 square centimeters with placebo. [5]

Curo, a peptide shop with the same owner as PepBank, has a related article. [Tesamorelin: A Peptide With a Drug Label, and Where to Buy It in 2026](https://curo.you/insights/tesamorelin-a-peptide-with-a-drug-label)

## What did the liver fat trials show?

In a trial in adults with HIV and abdominal fat accumulation, tesamorelin reduced liver fat more than placebo over 6 months. The median liver fat change was -2% with tesamorelin and 0.9% with placebo. The net treatment effect was -2.9%. [11]

A second trial in people with HIV and NAFLD ran over 12 months. Tesamorelin reduced hepatic fat fraction (HFF) more than placebo, with an absolute difference of -4.1%. In this trial in people, HFF showed a 37% relative reduction from baseline. [1]

## Did trunk muscle change when visceral fat fell?

In a trial in adults with HIV and abdominal obesity, responders were people whose visceral fat fell by 8% or more on tesamorelin. These responders had greater increases than placebo participants in the density of four trunk muscle groups. [2] In this trial in people, responders also gained more lean muscle area in all four groups. [2]

In the same trial in people, lean density rose more in responders in the abdominal muscles, with a coefficient of 1.39 Hounsfield units. The coefficient for the rectus muscles was 1.78 Hounsfield units. [2]

In this trial in people, the total area of the rectus muscles grew by 0.44 square centimeters more in responders than with placebo. The psoas muscles grew by 0.46 square centimeters more. [2]

## Did tesamorelin change insulin or blood sugar?

In a trial in adults with type 2 diabetes, tesamorelin did not change relative insulin response versus placebo over 12 weeks. [3] In a trial in adults with HIV and abdominal fat, tesamorelin caused no change in glucose parameters. [10]

In another trial in adults with HIV, fasting glucose rose more with tesamorelin than with placebo at 2 weeks. [11] At 6 months in that trial in people, the change in fasting glucose did not differ significantly from placebo. Neither did the 2-hour glucose change. [11]

## What did the cognition trial find?

In a trial in virally suppressed adults with HIV and abdominal obesity, researchers compared tesamorelin with standard of care. Tesamorelin reduced waist circumference more, with a median difference of -2.7 cm. [4] In this trial in people, neurocognitive performance showed a trend toward improvement, but the difference from standard of care was not significant. [4]

## What amounts did the trials in people use?

Randomized controlled trials in people studied tesamorelin at 2 mg, given subcutaneously. [5, 6, 11] A dose-ranging randomized controlled trial in people studied 1 mg and 2 mg, also given subcutaneously. [12]

| Kind | Dose | Species | Route | Design | Source |
| --- | --- | --- | --- | --- | --- |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [5] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [6] |
| Studied dose | 2 mg every day | people | subcutaneous | randomized controlled trial | [10] |
| Studied dose | 2 mg daily | people | subcutaneous | randomized controlled trial | [4] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [11] |
| Studied dose | 1 mg | people | subcutaneous | randomized controlled trial | [12] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [12] |
| Studied dose | 2 mg daily | people | subcutaneous | randomized controlled trial | [13] |

## Where do PepBank's records stand?

As of October 30, 2026, PepBank holds 37 publications with findings in people and 5 with findings in animals, by [evidence class](https://pepbank.io/methods). The records also list 23 registered trials that test tesamorelin. [7] PepBank records 288 results from [tesamorelin studies](https://pepbank.io/p/tesamorelin/studies) that gave the peptide. [7]

[Tesamorelin](https://pepbank.io/p/tesamorelin) is one of the [peptides in PepBank](https://pepbank.io/peptides), with 42 studies that gave it and reported results. [7] The FDA also approved Egrifta SV for the same use in adults with HIV and lipodystrophy. In 2025, it approved Egrifta WR for that use. [14, 15]

## FAQ

### Did the FDA approve tesamorelin?

The FDA approved Egrifta in the US in 2010 for reducing excess abdominal fat in adults with HIV and lipodystrophy. [9] The FDA also approved Egrifta SV for the same use, and it approved Egrifta WR in 2025. [14, 15] PepBank's regulatory record lists tesamorelin as approved in the US under the Egrifta name, with a 2010 date. [8]

### Does tesamorelin lower triglycerides or cholesterol?

In pooled trials in patients with HIV and excess abdominal fat, tesamorelin reduced triglycerides versus placebo at week 26. The treatment effect was -12.3%. [5] In the same trials in patients, it reduced the cholesterol to HDL ratio, with a treatment effect of -7.2%. [5] Another trial in patients found lower triglycerides and a lower cholesterol to HDL ratio versus placebo. [6]

### Does tesamorelin raise IGF-I levels?

In pooled trials in patients with HIV, mean IGF-I rose by 108 ng/ml with tesamorelin and changed by -7 ng/ml with placebo. [5] In another trial in patients, IGF-I rose 81% with tesamorelin and changed by -5% with placebo. [6] In a dose-ranging randomized trial in people, subcutaneous amounts of 1 mg and 2 mg raised IGF-I by 48% and 65%. [12]

### How did patients rate their belly after tesamorelin?

In pooled trials in patients with HIV and excess abdominal fat, tesamorelin improved belly appearance distress. [5] Patient and physician ratings of belly profile also improved in those trials in patients. [5] In a separate trial in adults with HIV, patient-rated distress and physician-rated belly profile improved versus placebo. [10] The pooled trials reported tesamorelin as generally well tolerated in patients. [5]

## Sources

1. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 2019-10-11. https://pubmed.ncbi.nlm.nih.gov/31611038/ PMID 31611038. Evidence class: human.
2. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. The Journal of frailty & aging, 2019-01-01. https://pubmed.ncbi.nlm.nih.gov/31237318/ PMID 31237318. Evidence class: human.
3. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one, 2017-06-15. https://pubmed.ncbi.nlm.nih.gov/28617838/ PMID 28617838. Evidence class: human.
4. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025-06-01. https://pubmed.ncbi.nlm.nih.gov/39813152/ PMID 39813152. Evidence class: human.
5. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of clinical endocrinology and metabolism, 2010-06-16. https://pubmed.ncbi.nlm.nih.gov/20554713/ PMID 20554713. Evidence class: human.
6. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine, 2007-12-01. https://pubmed.ncbi.nlm.nih.gov/18057338/ PMID 18057338. Evidence class: human.
7. Tesamorelin in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/tesamorelin
8. Tesamorelin: regulatory status in PepBank. PepBank, 2026-10-09. https://pepbank.io/p/tesamorelin
9. Egrifta (US). U.S. Food and Drug Administration (openFDA), 2026-10-09. https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22EGRIFTA%22
10. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of acquired immune deficiency syndromes (1999), 2010-03-01. https://pubmed.ncbi.nlm.nih.gov/20101189/ PMID 20101189. Evidence class: human.
11. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014-07-01. https://pubmed.ncbi.nlm.nih.gov/25038357/ PMID 25038357. Evidence class: human.
12. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (London, England), 2005-08-01. https://pubmed.ncbi.nlm.nih.gov/16052083/ PMID 16052083. Evidence class: human.
13. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PloS one, 2015-10-12. https://pubmed.ncbi.nlm.nih.gov/26457580/ PMID 26457580.
14. Egrifta SV (US). U.S. Food and Drug Administration (openFDA), 2026-10-09. https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22TESAMORELIN%22
15. Egrifta WR (US). U.S. Securities and Exchange Commission, 2026-10-09. https://www.sec.gov/Archives/edgar/data/0001512717/000119312525063760/d944896dex991.htm

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/what-did-tesamorelin-trials-test-beyond-belly-fat

This is not medical advice.
